Proteomics International Laboratories’s (ASX: PIQ) subsidiary OxiDx Pty Ltd has been granted a patent in Japan for its platform technology to measure oxidative stress.
The patent marks the first of a new family of patents for OxiDx’s next generation diagnostics technology and is another illustration of Proteomics International’s specialist platform technologies.
Oxidative stress is implicated in over 70 health conditions with levels often reflective of a person’s health and fitness.
Proteomics International Managing Director Dr Richard Lipscombe said the patent was a significant milestone towards commercialising OxiDx’s ground breaking technology across a range of key markets.
“Securing this IP protection in a major jurisdiction like Japan signifies a recognition of the uniqueness of the OxiDx intellectual property and bodes well for the OxiDx’s pending patent applications for this technology in other jurisdictions.”
Measuring oxidative stress has broad application across multiple markets including as a complementary diagnostic (CDx) test for assessing treatment efficacy and precision medicine by enabling personalised dosing in clinical trials, or as an athletic monitoring tool for competition preparedness and to reduce injuries in the Professional Sports and Horse Racing Industries.
Executive chair of OxiDx, Ian Brown said the technology is already well-proven with over 20 academic publications on its use including in diseases like Duchenne Muscular Dystrophy. “We are now embarking on field trials to demonstrate further applicability, initially in high-performance athletes and the horse racing industry. This patent helps ensure OxiDx’s technology is secured for many years to come, as we look forward to expanding into multiple markets and revolutionising the way oxidative stress is monitored and managed.”
OxiDx uses next generation diagnostics technology, moving beyond measuring protein concentrations to detect subtle changes in protein structures – ‘decorations’ that sit on the surface of a protein and are known as post-translational modifications.
The company’s platform technology measures systemic oxidative stress in a fingerpick blood sample by using a sensitive ratio-metric method to detect protein biomarkers in the blood. Samples can be collected in the home, clinic or on the field with high specificity to provide a comprehensive solution for monitoring oxidative stress levels.
